Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome

NCT03303066 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT03303066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03303066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome
Lead sponsor
Kyntra Bio
Phase
Phase 2/3
Overall status
Completed
Start date
June 6, 2018
Completion date
February 8, 2023
Enrollment
43 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, myelodysplastic syndrome